Individual patient SDAI responses during the DE period
REMISSION
In the subpopulation of patients who achieved early (at week 24) sustained SDAI remission, individual patient trajectory data presented as heatmaps show that more patients maintained SDAI remission at all study visits during the DE period if they continued abatacept (either abatacept + MTX, 53% [9/17] or abatacept monotherapy, 63% [10/16]) than if they de-escalated/withdrew abatacept (37% [7/19]) or received abatacept placebo + MTX (41% [7/17]; Fig. Individual SDAI responses (patients achieving early [IP week 24] sustained [through IP week 52